Results 81 to 90 of about 66,456,090 (253)

Model selection in preclinical nucleic acid therapeutics research [PDF]

Nucleic acid therapeutics (NATs) are a maturing drug class with many active clinical trials and a growing number of approvals. For NATs such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), a major hurdle during the research and ...
Hill, Alyssa C., Oliver, Peter L.
core   +1 more source

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

Molecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller, Janina Müller, Efstathios‐Iason Vlachavas, Lukas Beumers, Lena Fleischhacker, Sara Burmester, Angelika Wörner, Sabine Karolus, Dominic Helm, Cindy Körner, Stefan Wiemann   +10 more
wiley   +1 more source

Inhibition of cyclin‐dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation

Molecular Oncology, EarlyView.
The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington, Divya L. Dayanidhi, Mohammad Zokaasadi, John B. Mantyh, Pelumi D. Olawuni, Gabrielle Rupprecht, Jeremy M. Force, Shannon McCall, Ashwani K. Bahl, David S. Hsu, Jason A. Somarelli   +10 more
wiley   +1 more source

Remodeling Effect of HA Hybrid Cooperative Complexes on Dermal White Adipose Tissue and Its Structure

Clinical, Cosmetic and Investigational Dermatology
Immacolata Polvere,1 Mario Scrima,1 Nicoletta Vito,1 Giacomo Signorino,1 Antonio Iorio,1 Andrea Maria Giori,2 Angela Ferravante11Preclinical & Clinical Research and Safety Department, IBSA Corporate, Ariano Irpino, Italy; 2Preclinical & Clinical ...
Polvere I, Scrima M, Vito N, Signorino G, Iorio A, Giori AM, Ferravante A   +6 more
doaj  

Secretion of apolipoproteins A-I and B by HepG2 cells: regulation by substrates and metabolic inhibitors.

Journal of Lipid Research, 1995
It was the aim of this study to i) compare the effects of glucose and other hexoses with that of oleate on secretion of apolipoproteins (apos) A-I and B by HepG2 cells, and ii) document the effect of various metabolic inhibitors on the secretion of these
H.J. Kempen, A.P. Imbach, T Giller, W.J. Neumann, U Hennes, N Nakada   +5 more
doaj   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Single‐cell transcriptional atlas of human breast cancers and model systems

Clinical and Translational Medicine
Background Breast cancer's complex transcriptional landscape requires an improved understanding of cellular diversity to identify effective treatments. The study of genetic variations among breast cancer subtypes at single‐cell resolution has potential ...
Julia E. Altman, Amy L. Olex, Emily K. Zboril, Carson J. Walker, David C. Boyd, Rachel K. Myrick, Nicole S. Hairr, Jennifer E. Koblinski, Madhavi Puchalapalli, Bin Hu, Mikhail G. Dozmorov, X. Steven Chen, Yunshun Chen, Charles M. Perou, Brian D. Lehmann, Jane E. Visvader, J. Chuck Harrell   +16 more
doaj   +1 more source

Effects of stigmastanyl-phosphocholine (Ro 16-6532) and lovastatin on lipid and lipoprotein levels and lipoprotein metabolism in the hamster on different diets

Journal of Lipid Research, 1995
Previous studies from our laboratory have shown that oral administration of stigmastanyl-phosphocholine (Ro 16-6532) reduces plasma cholesterol levels in experimental animals on diets free of added cholesterol. In the present study, effects of Ro 16-6532
J Himber, B Missano, M Rudling, U Hennes, H J Kempen   +4 more
doaj   +1 more source

Innovative preclinical models for pulmonary drug delivery research.

, 2020
Introduction: Pulmonary drug delivery is a complex field of research combining physics which drive aerosol transport and deposition and biology which underpins efficacy and toxicity of inhaled drugs.
Vecellio, L., Barosova, Hana, Schmid, O., Schmid, Otmar, Sznitman, Josue, Vecellio, Laurent, Barosova, H., Rothen-Rutishauser, Barbara, Yang, L., Sznitman, J., Henze-Vourc´h, N., Yang, Lin, Ehrmann, S., Mitchell, Jolyon, Heuzé-Vourc'H, Nathalie, Ehrmann, Stephan, Darquenne, Chantal, Heuze-Vourc’h, Nathalie, Darquenne, C., Mitchell, J., Rothen-Rutishauser, B., Rothen-Rutishauser B, Vecellio L, Schmid O, Barosova H, Darquenne C, Heuze-Vourc'h N, Mitchell J, Yang L, Ehrmann S, Sznitman J   +30 more
core   +1 more source

The Economics of Reproducibility in Preclinical Research. [PDF]

, 2015
Low reproducibility rates within life science research undermine cumulative knowledge production and contribute to both delays and costs of therapeutic drug development.
Leonard P. Freedman (752097), Iain M Cockburn, Timothy S. Simcoe (752099), Simcoe, Timothy S., Timothy S Simcoe, Iain M. Cockburn (752098), Cockburn, Iain M., Leonard P Freedman, Freedman, Leonard P., Freedman Leonard P., Simcoe Timothy S., Cockburn Iain M.   +11 more
core   +2 more sources